Levosimendan 2.5 mg/ml Injectable Solution

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Hypertension Pulmonary Secondary Heart Failure

Drug Information

Target Indication

Hypertension Pulmonary Secondary Heart Failure

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

TENX

TENAX THERAPEUTICS, INC.

Related Pipeline

Pulmonary Hypertension

Hypertension Pulmonary Secondary

Traumatic Brain Injury

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts